Glythera partners with FDA to assess protein technology
This article was originally published in Scrip
Executive Summary
Glythera is to work with the US FDA's Center for Biologics Evaluation and Research to assess the feasibility of applying the UK-based biotech's PermaLink technology to the generation of synthetic carbohydrate-based conjugate vaccines.